DAX25.088 +0,2%Est506.078 +0,3%MSCI World4.343 -0,1%Top 10 Crypto8,6500 +1,5%Nas22.683 -0,3%Bitcoin56.865 ±-0,0%Euro1,1758 -0,1%Öl71,43 -0,7%Gold5.044 +1,0%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
Rheinmetall 703000 Bayer BAY001 SAP 716460 Siemens Energy ENER6Y NVIDIA 918422 Deutsche Telekom 555750 Infineon 623100 Airbus 938914 Amazon 906866 Microsoft 870747 Lufthansa 823212 RENK RENK73 BASF BASF11 Siemens 723610 DroneShield A2DMAA
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Dow leichter erwartet -- DAX etwas höher -- Pentagon-Liste belastet BYD, Alibaba & Co -- NVIDIA wohl mit Milliardeninvestment in OpenAI -- Apple, Telekom, BioNTech, Moderna, Bayer, Airbus im Fokus
Top News
NVIDIA, Amazon & Co.: In diese Aktien hat George Soros im vierten Quartal 2025 investiert NVIDIA, Amazon & Co.: In diese Aktien hat George Soros im vierten Quartal 2025 investiert
Zeitenwende an den Aktienmärkten? Ray Dalio erklärt das Ende der Nachkriegsordnung Zeitenwende an den Aktienmärkten? Ray Dalio erklärt das Ende der Nachkriegsordnung
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Jazz Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
143,50 EUR -0,55 EUR -0,38 %
STU
169,73 USD +1,02 USD +0,60 %
vorbörslich
BTT
Jazz Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.8,72 Mrd. EUR

KGV14,24Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA1JS1K

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINIE00B4Q5ZN47

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolJAZZ

Jazz Pharmaceuticals Aktien News

DatumMeistgelesen
finanzen.netJazz Pharmaceuticals zog Bilanz zum jüngsten Jahresviertel
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
PR NewswireJazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic H...
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswireJazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
PR NewswirePharmaMar gibt positive und statistisch signifikante Ergebnisse zum Gesamtüberleben und zum progressionsfreien Überleben für die Kombination aus Zepzelca® (Lurbinectedin) und Atezolizumab in der E...
PR NewswirePharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenan...
PR NewswireJazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance...
PR NewswireJazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
PR NewswireJazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
PR NewswireJazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
PR NewswireJazz Pharmaceuticals Provides Update on Cannabidiol Oral Solution Phase 3 Trial in Japan in Treatment-Resistant Epilepsies
PR NewswireJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming September Investor Conferences
finanzen.netJazz Pharmaceuticals informierte über die jüngsten Quartalsergebnisse
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces Second Quarter 2024 Financial Results and Updates 2024 Financial Guidance
finanzen.netAusblick: Jazz Pharmaceuticals stellt das Zahlenwerk zum vergangenen Quartal vor
PR NewswireJazz Pharmaceuticals Shareholders Elect Laura Hamill to the Company's Board of Directors at Annual General Meeting
PR NewswireJazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
PR NewswireJazz Pharmaceuticals Announces Successful Completion of Term Loan Repricing and Irrevocable Election of Settlement Method for the 2.000% Exchangeable Senior Notes due 2026
PR NewswireJazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
PR NewswireJazz Pharmaceuticals to Report 2024 Second Quarter Financial Results on July 31, 2024
PR NewswireJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
PR NewswireJazz Pharmaceuticals Promotes Samantha Pearce to Chief Commercial Officer
PR NewswireJazz Pharmaceuticals Provides Update on Phase 2b Trial of Investigational Suvecaltamide (JZP385) in Essential Tremor
PR NewswireJazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024
PR NewswireJazz Pharmaceuticals Showcases Pioneering Research in Sleep Medicine at SLEEP 2024
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireJazz Pharmaceuticals to Participate in Upcoming June Investor Conferences
PR NewswireZanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
PR NewswireJazz Pharmaceuticals Announces Collaboration with Life Science Cares to Improve the Wellbeing of Under Resourced Communities through Employee Volunteerism
finanzen.netJazz Pharmaceuticals: Bilanz zum abgelaufenen Quartal
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
PR NewswireJazz Pharmaceuticals to Participate in the BofA Securities 2024 Health Care Conference
PR NewswireJazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
PR NewswireJazz Pharmaceuticals Announces First Quarter 2024 Financial Results and Affirms 2024 Financial Guidance
finanzen.netAusblick: Jazz Pharmaceuticals präsentiert Quartalsergebnisse
PR NewswireJazz Pharmaceuticals to Present Data Across Growing Oncology Pipeline and Portfolio at ASCO 2024

Jazz Pharmaceuticals News

Jazz Pharmaceuticals News: auf dieser Seite finden Sie alle Jazz Pharmaceuticals News und Nachrichten zur Jazz Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Jazz Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Jazz Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.